Funding Announced for Development of a Vaccine for Disease Affecting Global Poor
Bill & Melinda Gates Foundation to provide Sabin Vaccine Institute with $12 million to fund multiple phase 1 clinical trials and further product development for human hookworm vaccine
WASHINGTON D.C. -- Sabin Vaccine Institute (Sabin) today announced receipt of a two-year, $12 million grant from the Bill & Melinda Gates Foundation to continue development of a vaccine to prevent human hookworm infection, a parasitic disease that affects 600 million people worldwide.
Hookworm infection, most commonly found in sub-Saharan Africa, Southeast Asia and Latin America, is a significant contributor to the global burden of iron-deficiency anemia that disproportionately affects children and women of reproductive age.
To read the full press release, visit the Sabin Vaccine Institute web site.